The Base to Base Biotech podcast is a weekly look at what's happening in the world of biotech, with interviews with biotech leaders around the world.
Whether it's a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed.
The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall.
Base to Base is an Ayr Coastal Media Ltd production.
Site
RSS
Apple
Data updated on 14/07/2026
Recent rankings
Latest chart positions across Apple Podcasts and Spotify rankings.
Shared links between episodes and podcasts
Links found in episode descriptions and other podcasts that share them.
Base to Base biotech podcast 50: Drugs for kidney transplants, glycans, and drug delivery
Episode 50
Friday, March 13, 2026 • Duration 01:11:50
As this week’s podcast comes hot on the heels of International Women’s Day and World Kidney Day, which was yesterday, we’ve been able to squeeze them both in. The conversations this week are with Hansa Biopharma CEO Renée Aguiar-Lucander, about imlifidase for kidney transplant patients; Kyron.bio CEO Emilia McLaughlin, about glycosylation; and hydrogel-based drug delivery solutions company AmacaThera’s CEO, Mike Cooke.
Times:
03:56 Kyron.bio
19:14 AmacaThera
43:01 Hansa Biopharma
Hansa Biopharma
Hansa Biopharma AB is set for a busy year. In December, the Food and Drug Administration (FDA) has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been assigned a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2026.
Imlifidase is conditionally approved in the EU, Norway, Liechtenstein, Iceland and the UK under the tradename IDEFIRIX for the desensitisation treatment of highly sensitised adult kidney transplant patients with a positive crossmatch against an available deceased donor. IDEFIRIX is also approved in Australia and Switzerland.
The company also has HNSA-5487, a next-generation IgG-cleaving molecule being developed for Guillain-Barré Syndrome (GBS).
Kyron.bio
French biotech company Kyron.bio and pharma company Servier recently announced a partnership to advance precision glycosylation in antibody therapeutics.
The partnership underlines the two companies’ vision to unlock the potential of glycans in next-generation biologics design to deliver safer and more effective therapeutics for patients
Kyron.bio’s glycobiology platform aims at enhancing the efficacy, safety, and scalability of next-generation antibody therapeutics across multiple disease areas. To date, engineering of glycans have been under-exploited, due to technical challenges, limiting the use of glycan engineering in drug design.
AmacaThera
AmacaThera is a developer of next-generation hydrogel-based drug delivery solutions. Using a blend of known polymers, AmacaThera’s clinically validated hydrogel platform is transforming drug delivery by enabling the precise, tunable, and sustained release of a range of therapeutics, from small molecules to biologics.
Transforming from liquid to gel at body temperature, AmacaThera’s hydrogel enables drugs to be delivered to and stay where they are needed and released over days or weeks, depending on the specific needs of each therapeutic application.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com
Base to Base biotech podcast 49: Gene therapy for kidney disease, and using AI to transform diagnostics
Episode 49
Friday, March 6, 2026 • Duration 51:32
This week, we’re chatting with Haseeb Ahmad, CEO of Purespring Therapeutics, about gene therapies in kidney disease, and with Pahini Pandya, Panakeia CEO, about colorectal cancer biomarkers, the potential of AI in clinical decision-making and how AI can transform workflows in diagnostics.
Times:
03:34 Purespring
24:11 Panakeia Technologies
Purespring Therapeutics
Purespring is a precision nephrology company pioneering first-in-class, targeted genetic therapies designed to preserve kidney function.
The company is focused on transforming the treatment of kidney disease—an area of enormous unmet need, with more than 840m people worldwide living with chronic kidney disease.
Purespring’s lead programme, PS-002, for IgA nephropathy (IgAN) is set to enter the clinic this quarter. It marks the first podocyte-targeted gene therapy to reach clinical development and offers a highly differentiated approach compared with other emerging treatments, including those from Vertex and Otsuka.
Panakeia Technologies
Panakeia Technologies recently published a real-world clinical validation showing that AI can determine critical colorectal cancer biomarkers in minutes, in a test across 1,243 patients and 3,576 images in NHS hospitals.
While not yet used directly in patient care, the study demonstrates the potential for AI to support clinical decision-making, reduce lab bottlenecks, and help clinicians act faster — a topic highly relevant to the goals of the UK government's cancer plan and the ongoing discussion around innovation in healthcare.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com
Base to Base biotech podcast 48: GPCRs and beating neurodegenerative diseases
Episode 48
Friday, February 27, 2026 • Duration 52:47
The conversations on this week’s podcast are with CEO of Merz Therapeutics, Stefan König, about a variety of neurodegenerative conditions and a botulinum neurotoxin, and with CEO of Kainova Therapeutics, Sean MacDonald, about – among other things – G-protein coupled receptors, or GPCRs.
Times:
03:21 Merz Therapeutics
30:34 Kainova Therapeutics
Kainova Therapeutics
Kainova Therapeutics is a clinical-stage biopharmaceutical company headquartered in Montreal, Canada. The company develops drug candidates targeting GPCRs, with programmes focused on immuno-oncology and inflammatory diseases.
The company’s pipeline includes antibody and small-molecule programmes directed at GPCR targets. These include a CCR8-targeting antibody programme being evaluated in oncology, as well as PAR2 and EP4 antagonist programmes with potential applications in inflammatory conditions. Its development activities span preclinical and early clinical stages.
Kainova was previously known as Domain Therapeutics.
Merz Therapeutics
Merz Therapeutics is a pharmaceutical company headquartered in Frankfurt, Germany. It operates as the therapeutics arm of the Merz Group and focuses on the development and commercialisation of medicines for neurological and neuro-related conditions.
The company’s portfolio includes treatments used in areas such as movement disorders, spasticity and other neurological conditions.
Merz Therapeutics also engages in focused acquisitions and partnerships to broaden its portfolio and reach more patients globally.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com
Base to Base biotech podcast 47: Accurate prostate cancer diagnosis and ocular gene therapy
Episode 47
Friday, February 20, 2026 • Duration 01:01:01
The conversations on this week’s podcast focus on a rapid and accurate prostate cancer diagnostic test, with Valley Diagnostics’ CEO Dave Taylor; and on gene therapy for retinal disease, with Lance Baldo, CEO of Beacon Therapeutics.
Times:
03:12 Beacon Therapeutics
27:38 Valley Diagnostics
Valley Diagnostics
Valley Diagnostics is a Welsh company developing next‑generation lateral flow diagnostic tests designed for early detection of human and animal diseases.
Their approach uses patented biomarkers to make faster and more accurate screening possible in GP surgeries, point‑of‑care settings, and at home. Their current pipeline includes tests for prostate cancer, lung cancer, and bovine tuberculosis.
The company is working with academic and clinical partners across Wales and England to validate its biomarkers through large‑scale studies. One example is the OSCAR clinical study, which is screening thousands of urine samples to support development of a rapid prostate cancer test.
In recent weeks, Valley Diagnostics signed several licensing agreements with Aberystwyth University, securing exclusive global rights to biomarker IP across four major disease areas. These agreements are intended to support commercialisation of their point‑of‑care tests and move them toward market readiness.
Beacon Therapeutics
Beacon Therapeutics is an ocular gene therapy company focused on inherited retinal diseases, including X‑linked retinitis pigmentosa (XLRP).
Earlier this month, the company announced it had raised over $75m in an oversubscribed Series C financing led by Life Sciences at Goldman Sachs Alternatives and with participation from the Retinal Degeneration Fund (RD Fund), the venture arm of Foundation Fighting Blindness.
Base to Base biotech podcast 46: Endometriosis and closing care gaps
Episode 46
Friday, February 13, 2026 • Duration 48:02
The conversations on this week’s podcast are with Vibhor Gupta, director and founder of Pangaea Data, and endogene.bio CEO María Teresa Pérez Zaballos.
endogene.bio is a precision medicine company based in France developing a non-invasive diagnostic for endometriosis. The company’s aim is to apply precision medicine to female health.
The company was formed in 2022 by Maria Teresa Perez Zaballos and Cristina Fernandez Molina. Its innovations include a non-invasive diagnostic approach that uses menstrual blood rather than traditional blood draws or invasive surgery. By focusing on the uterine environment directly, the company aims to replace the current "gold standard" of laparoscopic surgery with a high-signal "liquid biopsy" that can be collected at home.
The company recently published a preprint, “Beyond one-size-fits-all: single-cell transcriptomic signatures predict drug efficacy and reveal responder subgroups in endometriosis.”
The company’s most recent scientific output, it was published in January 2026, and shows how the company uses single-cell transcriptomic signatures to map the molecular heterogeneity of the disease. The research has identified distinct "responder subgroups," suggesting that endometriosis is not a single condition but a collection of cellular programmes that dictate how a patient will react to specific therapies. This primary data positions endogene.bio’s platform as both a diagnostic tool and a predictive framework for patient stratification in clinical trials, aiming to move the field toward personalized treatment selection.
Pangaea Data
Pangaea Data provides a clinical-grade AI platform, PALLUX, designed to identify untreated, misdiagnosed, and under-treated patients by extracting intelligence from unstructured records.
Base to Base biotech podcast 45: Chronic pain, urology, Affibody molecules and radioligand therapy
Episode 45
Friday, February 6, 2026 • Duration 45:23
This week, we chat with Affibody CEO David Bejker, and Martin Gleave, founder and chief medical officer at Sustained Therapeutics.
Times:
03:47 Affibody
23:28 Sustained Therapeutics
Sustained Therapeutics
A spin-out from the University of British Columbia in Canada, Sustained Therapeutics utilises a proprietary polymer gel technology to develop locally injected, long-acting medications. The platform is designed to release active pharmaceutical ingredients in a controlled manner over several weeks, aiming to replace traditional oral delivery or frequent injections.
While the primary focus is on managing acute and chronic pain without the use of opioids, the company is also exploring applications for the technology in inflammatory diseases and urology.
The core of the company’s pipeline involves a non-addictive, sustained-release formulation that targets the site of pain directly. By providing localized treatment, the technology seeks to minimize systemic side effects and reduce the patient's reliance on addictive substances. Beyond pain management, the firm is adapting its delivery system for oncological use, specifically targeting upper tract urothelial carcinoma, where localized, prolonged drug exposure is clinically advantageous.
In January 2026, the company reported positive data from its phase II clinical trial for a long-acting non-opioid medication designed for chronic pain. The results indicated that the sustained-release mechanism effectively extended pain relief while maintaining a favourable safety profile. These findings support the continued expansion of their clinical program into other chronic pain indications, including pelvic and scrotal pain, which are slated for further study throughout the year.
Affibody
, a Swedish clinical-stage biopharmaceutical firm, is developing a new class of small proteins known as Affibody molecules. These engineered proteins are significantly smaller than traditional monoclonal antibodies—roughly one-tenth the size—which allows for better tissue penetration and flexible formatting for multi-specific treatments. The company’s research spans two main pillars: immunology and radiopharmaceuticals, leveraging its library of more than 10bn unique protein sequences to identify highly specific binders for various disease targets.
Base to Base biotech podcast 44: Treating breast cancer and how a CDMO and immun0-oncology company collaborate
Episode 44
Friday, January 30, 2026 • Duration 47:04
This week, we chat with Pan Cancer T CEO Dr. Rachel Abbott, about – among other things – triple-negative breast cancer. We also have a conversation with Erik Manting, CEO of immunotherapy company Mendus, and Janet Hoogstraate, CEO of the CDMO helping them, North X Biologics.
Times:
03:56 Pan Cancer T
20:23 Mendus/NorthX Biologics
Mendus
Mendusis a Swedish–Dutch immuno-oncology company developing cell-based therapies aimed at stopping cancers from coming back rather than treating only the initial tumour. Its lead product, vididencel, is an off‑the‑shelf dendritic cell vaccine being developed as a post‑remission therapy for patients with acute myeloid leukaemia (AML), and more recently chronic myeloid leukaemia, who remain at high risk of relapse after standard treatment. Mendus’ pipeline explores how active immunotherapies could extend treatment‑free survival in different myeloid malignancies.
In 2025, Mendus refined its strategy for vididencel on the back of positive data from a phase 2a trial in high‑risk AML, where long‑term follow‑up has shown durable remissions and an encouraging safety profile. Vididencel is also being studied in a phase 2b trial in combination with oral azacitidine, aimed at broadening its use beyond patients with measurable residual disease.
NorthX Biologics
North X Biologics is a contract development and manufacturing organisation (CDMO) and national innovation hub for complex biologics in Sweden. The company provides GMP‑grade development and manufacturing services for plasmid DNA, recombinant proteins, viral vectors, and cell & gene therapies from its facilities in Matfors and on the Karolinska University Hospital campus in Stockholm. Its goal is to give emerging biotechs and academic groups access to infrastructure and regulatory expertise that would be hard to build alone.
Base to Base biotech podcast 43: Natural killer cell therapy and attacking tumours
Episode 43
Friday, January 23, 2026 • Duration 50:27
This week, we have a conversation with Lisa Guerrettaz, executive director, Pharmacology and Translational Science at Artiva Biotherapeutics; and Avacta Therapeutics’ CEO Christina Coughlin.
Times:
04:12 Artiva Biotherapeutics
21:30 Avacta Therapeutics
Artiva Biotherapeutics
Artiva Biotherapeuticsis a clinical‑stage cell therapy company developing off‑the‑shelf (allogeneic) natural killer (NK) cell therapies for autoimmune diseases and cancer. Headquartered in San Diego and founded in 2019, the company was created as a spin‑out from GC Cell (formerly GC Lab Cell) in South Korea, alongside a strategic partnership granting Artiva exclusive rights (outside Asia, Australia and New Zealand) to GC Cell’s NK manufacturing technology and associated programmes.
Artiva’s lead programme is AlloNK, a non‑genetically modified, cryopreserved NK cell therapy designed to enhance antibody‑dependent cellular cytotoxicity (ADCC) when paired with monoclonal antibodies. The company positions this approach to achieve deep B‑cell depletion in outpatient settings without the complexity and cost associated with bespoke autologous cell therapies.
In terms of clinical activity, AlloNK is being evaluated across three ongoing trials in B‑cell‑driven autoimmune diseases, including company‑sponsored and investigator‑initiated basket studies covering indications such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis and Sjögren’s disease. Artiva has treated more than 100 patients with AlloNK across oncology and autoimmune disease and is planning FDA interactions in the first half of 2026 aimed at enabling a pivotal trial pathway in rheumatoid arthritis.
Avacta Therapeutics
Avactais a life sciences company best known for its Affimer platform—engineered binding proteins positioned as an alternative to antibodies for use in diagnostics, reagents and therapeutics. The company’s activities span both life science reagents/diagnostics and oncology therapeutics, with the latter centred on its pre|CISION technology, which is designed to activate drugs selectively in the tumour microenvironment.
Base to Base biotech podcast 42: Treating blood cancers, Scottish Brain Sciences and One BioHub Aberdeen, and is speech the new blood?
Episode 42
Friday, January 16, 2026 • Duration 01:16:16
This week, three interviews, and five guests. We have conversations with Ulrik Tirsted Zeuthen, CEO, and Katarina Cantell, founder/CSO of Adalyon; Nisit Khandelwal, co-founder/CEO, Cycuria Therapeutics; and Craig Ritchie, founder/CEO of Scottish Brain Sciences and Deborah O’Neil, CEO/CSO of NovaBiotics as well as chair of the Life Sciences board of Opportunity Northeast, which runs ONE BioHub, and BioAberdeen.
Times:
02:38 Adalyon
32:44 Cycuria Therapeutics
53:43 Scottish Brain Sciences/One BioHub
Cycuria Therapeutics
Cycuria Therapeutics is a preclinical oncology company based in Graz, Austria, which is developing first‑in‑class protein therapeutics for hard‑to‑treat blood cancers. Its lead programme, CUR‑101, is designed to target both acute myeloid leukaemia (AML) tumour cells and the tumour stem cells thought to drive relapse, while sparing healthy blood formation.
The company combines cytokine biology with protein engineering to deliver durable efficacy alongside a better safety profile in preclinical models.
Cycuria recently announced significant public grant funding to support the translation of CUR‑101 and follow‑on assets into the clinic.
Scottish Brain Sciences
Scottish Brain Sciences runs brain health research centres that specialise in clinical trials for early detection and treatment of neurodegenerative disease, with a particular focus on Alzheimer’s.
Scottish Brain Sciences is building one of the world’s largest biobanks of genetic, blood and imaging data in neurodegenerative conditions. It has helped more than 100 people with Alzheimer’s enrol into drug trials, and is leading the IONA longitudinal cohort study to characterise very early disease changes and prevent progression to dementia.
Base to Base biotech podcast 41: Eyes, mitochondria and a growing hub
Episode 41
Friday, January 9, 2026 • Duration 53:30
This week, we’re talking about eye treatments with Oculis CEO, Riad Sherif, we have a conversation about mitochondria, with the CEO of Vandria, Klaus Dugi, and there’s also a short discussion about GoCo Health Innovation City in Gothenburg, Sweden, with Moa Dicksdotter, Partnership and Ecosystem.
Times:
02:35 Vandria
20:03 GoCo Health Innovation City
25:54 Oculis
Looking to the eyes
Oculis is a Swiss ophthalmology company developing topical and biologic treatments for retinal disease and neuro‑ophthalmic conditions. Its pipeline spans diabetic macular oedema, dry eye disease, and optic neuropathies, with a focus on non‑invasive delivery formats that can replace or reduce the need for injections. The company’s lead asset, OCS‑01, is in late‑stage development as a topical alternative for diabetic macular oedema.
In December, the U.S. FDA granted Breakthrough Therapy Designation to Oculis’ neuroprotective candidate, Privosegtor (OCS‑05), for optic neuritis. The decision followed phase 2 data showing clinically meaningful improvements in low‑contrast visual acuity. The designation allows for closer FDA interaction as the programme moves toward registrational studies.
Oculis is now preparing for multiple clinical milestones across 2026, including pivotal readouts for OCS‑01. The company continues to position itself around differentiated delivery technologies in ophthalmology, with programmes spanning both front‑ and back‑of‑the‑eye disorders.
Mitochondrial therapeutics
Vandria is a Lausanne‑based biotech developing small‑molecule mitophagy activators aimed at restoring mitochondrial quality control in age‑related and chronic diseases. Its approach centres on orally available compounds designed to improve cellular resilience in neurological and muscular disorders. The company’s lead programme, VNA‑318, is being advanced for neurodegenerative indications.
The new funds will be used to complete the development of lead programme, laru-zova, a potential best-in-class gene therapy currently being investigated for the treatment of patients with XLRP, and progress commercialisation plans. The funds will also be used to help support the development of Beacon’s pipeline candidates for geographic atrophy, as well as an inherited cone rod dystrophy, and another undisclosed asset.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com
The platform emulates clinical reasoning to scan doctors’ notes and pathology reports, identifying care gaps across conditions such as oncology, rare diseases, and chronic kidney disease. It operates behind the healthcare organisation's firewall to ensure data privacy while integrating directly into existing EHR workflows and ambient listening tools.
The platform's "Privacy by Design" architecture allows it to scale across multiple disease areas without the need for manual data labelling. By mapping clinical features and disease trajectories, PALLUX provides clinicians with a single dashboard to access actionable insights. The methodology is currently deployed across 13 countries, helping pharmaceutical companies and healthcare providers discover up to five times more patients who would otherwise be missed by conventional search methods.
In December 2025, the London-headquartered company announced a multi-year strategic collaboration with AstraZeneca to advance precision healthcare through multimodal AI. The collaboration focuses on co-developing an enterprise-grade platform that fuses clinical, imaging, and genomic data to improve real-time treatment recommendations and speed up clinical trial recruitment.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com
Affibody
Recent activity has centred on a significant financial and clinical milestone. In late January 2026, the company launched a $29m rights issue, fully guaranteed by its lead shareholder, to fund its expanding radiopharmaceutical pipeline. This capital injection follows successful early-stage data for its RLT candidate, ABY-271; a Trial Review Committee recently recommended advancing the candidate to the second part of a phase I study in HER2-positive metastatic breast cancer after initial patient cohorts showed promising safety and biodistribution.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com
NorthX has expanded into cell therapy manufacturing, adding capabilities for multiple cell types, including pluripotent stem cells. The organisation aims to strengthen Sweden’s role as a European centre for advanced therapy medicinal products (ATMPs).
NorthX has collaborated with Mendus since 2023. In late 2025, they announced successful GMP manufacturing certification for vididencel at NorthX’s facilities, which supports Mendus’ upcoming late‑stage clinical trials and eventual commercial supply.
Pan Cancer T
Pan Cancer T brings a different angle to cancer immunotherapy, focusing on engineered T cell receptor (TCR‑T) therapies for hard‑to‑treat solid tumours.
Based in Rotterdam and spun out from Erasmus MC in 2020, the company is building a pipeline around tumour‑specific antigens that are consistently and strongly expressed across multiple cancers. Its lead programme, PCT1:CO‑STIM, is being developed for women with triple‑negative breast cancer, an aggressive form of the disease with limited treatment options and poor survival once it has spread.
By focusing on shared antigens across different tumour types, Pan Cancer T aims to develop treatments that could, in time, be applied beyond breast cancer to other solid tumours including melanoma and cancers of the skin, colorectum, stomach, oesophagus, ovary and uterus.
In December 2025, the company announced €10m financing to move PCT1:CO‑STIM into its first‑in‑human clinical trial in the Netherlands.
To get in touch with guest suggestions, or to advertise on the podcast, contactjim@deeptechdigest.com
In therapeutics, Avacta’s most advanced programme is faridoxorubicin (AVA6000), which uses a fibroblast activation protein (FAP)‑targeted mechanism intended to release an active form of doxorubicin preferentially at tumour sites. The programme has moved into phase 1b expansion cohorts to assess efficacy in more homogeneous patient populations and help guide expectations for later‑stage studies.
Earlier this month, the company announced U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for its FAP-Exd programme, the first pre|CISION peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com
The company recently opened a new office at ONE BioHub in Aberdeen.
One BioHub
ONE BioHub is a £40m life sciences innovation hub on Aberdeen’s Foresterhill Health Campus, created for high‑growth life science ventures in the north‑east of Scotland. The facility brings together start‑ups, spin‑outs and scaling companies with flexible labs, offices and grow‑on space, alongside commercialisation and skills programmes.
Led and co‑funded by Opportunity North East with support from the UK and Scottish governments, Scottish Enterprise and regional partners, ONE BioHub can accommodate up to 400 bio‑entrepreneurs. The aim is to accelerate research from the University of Aberdeen, Robert Gordon University and NHS Grampian into market‑ready solutions, diversifying the regional economy and creating life sciences jobs.
Adalyon
Adalyon develops AI‑driven speech biomarkers to serve as digital endpoints in clinical trials, helping sponsors detect treatment response earlier and manage patient engagement. Its platform analyses natural speech from voice journalling or guided conversations to extract behavioural, emotional and paralinguistic features relevant to psychiatric and neurological conditions.
The company combines AI engineering, clinical research operations and behavioural science to build tools that align with regulatory expectations for digital endpoints. Its technology is designed to automate aspects of psychometric assessment, flag dropout risk and shorten trial timelines by enabling earlier, objective insight into how patients are responding to therapy.
In November 2025, Vandria released phase 1 results for VNA‑318, reporting that the study met its safety and pharmacokinetic objectives and showed biomarker evidence of target engagement. The data support progression into phase 2 development for Alzheimer’s disease, with trial planning now under way.
The company is also preparing for its next financing round to support clinical expansion and further development of its mitochondrial therapeutics platform.
GoCo Health Innovation City
GoCo Health Innovation City is a life‑science district in Mölndal, south of Gothenburg, Sweden, designed as a mixed ecosystem for research, industry, and healthcare organisations. The campus brings together established companies, scale‑ups, and academic groups across health, biotech, and medtech, with a focus on co‑located labs, offices, and community‑driven programmes.
Recently, the site marked a major milestone with the opening of Mölnlycke Health Care’s new global headquarters on the campus. The inauguration brought renewed attention to GoCo’s role as a strategic hub for Swedish life‑science activity and its ability to attract multinational tenants.
The district is continuing to expand its research infrastructure. Thermo Fisher Scientific is establishing a new bioanalytical laboratory on the campus, scheduled to open in late 2025. The facility will support pharmaceutical and biotech clients with GLP‑compliant services and is expected to add significant analytical capacity to the region.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com
Related Shows Based on Content Similarities
Discover shows related to Base to Base Biotech, based on actual content similarities. Explore podcasts with similar topics, themes, and formats, backed by real data.
